Business Context and Reporting Period
This Form 8-K is a current report filed by ADVENTRX Pharmaceuticals, Inc. (not Savara Inc.) on January 8, 2009. The filing discloses the effective date of a Confidential Separation Agreement regarding the departure of a senior executive.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to a specific severance obligation:
- Severance Payment: $165,500
- Health Benefit Allowance: $18,352
- Total Compensation Obligation: $183,852 (subject to withholdings)
Material Changes
The material change reported is the departure of Mark N.K. Bagnall, who served as Executive Vice President, Chief Financial Officer, and Treasurer. His employment ended on December 26, 2008. He remains a member of the Board of Directors and will provide consulting services on an as-needed basis.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, market outlook, or general risk factors. The primary contingency noted is the execution of the Separation Agreement, which supersedes previous severance provisions outlined in Mr. Bagnall's offer letter (effective April 3, 2008, and amended December 11, 2008). The payments are scheduled to be made in a lump sum on the Company's next regular payday.
Investor Verification Checklist
- Verify the exact timing of the lump-sum payment to confirm the impact on the next quarter's cash flow.
- Confirm the interim appointment of a new Chief Financial Officer or Treasurer, as the filing does not name a replacement.
- Review the Company's cash position to ensure the $183,852 obligation does not strain liquidity.
- Check subsequent filings for any changes to the Board of Directors composition regarding Mr. Bagnall's continued service.